Zobraziť v EDS

The Role of Ga-68-PSMA PET/CT in the Initial Staging of Prostate Cancer – A Single Center 4 Year Experience

Uložené v:
Podrobná bibliografia
Názov: The Role of Ga-68-PSMA PET/CT in the Initial Staging of Prostate Cancer – A Single Center 4 Year Experience
Autori: João P Lima, João Carvalho, Vasco Quaresma, Edgar Tavares-da-Silva, Rodolfo Silva, Paulo Azinhais, Gracinda Costa, Arnaldo Figueiredo
Zdroj: Res Rep Urol
Research and Reports in Urology, Vol Volume 13, Pp 479-485 (2021)
Informácie o vydavateľovi: Informa UK Limited, 2021.
Rok vydania: 2021
Predmety: 03 medical and health sciences, pet-ct, 0302 clinical medicine, bone metastases, Research and Reports in Urology, lymphatic metastases, metastasis, RC870-923, prostate cancer, specificity and sensitivity, Diseases of the genitourinary system. Urology, Original Research, 3. Good health
Popis: Recommended imaging modalities for prostate cancer staging have disappointing sensitivities, whereas [68Ga]-PSMA PET/CT (PET-PSMA) shows promising sensitivities and specificities in the initial management of prostate cancer. Recent studies have revealed that a significant change of management when PET-PSMA was used, with favorable negative predictive values.In this retrospective study, we analyzed every PET-PSMA performed in our center for initial staging of intermediate and high-risk prostate cancer. Patients were divided into two groups based on whether imaging modalities other than PET-PSMA were performed. In patients submitted to radical prostatectomy, PET-PSMA findings were compared to histological analysis of the specimen.PET-PSMA results of 57 patients were gathered, with 77.2% (n=44) having performed CT scan or bone scan (BS) prior to PET-PSMA. Prostate cancer management strategy was changed in 61.4% (n=27), when PET-PSMA was performed following CT and BS. BS and CT results were consistent with PET-PSMA in 43.2% and 44.8%, respectively. In 30 cases, a curative strategy was used based on PET-PSMA findings. PET-PSMA revealed a negative predictive value of 95.2% in 23 patients submitted to radical prostatectomy with bilateral pelvic lymphadenectomy. Prostate SUV values on preoperative PET-PSMA correlated with initial PSA, ISUP grade, PC risk staging and presence of extraprostatic lesions.PET-PSMA is a key element for prostate cancer staging and management, with high diagnostic accuracy. More prospective studies need to be implemented to determine its role as a first-line staging tool.
Druh dokumentu: Article
Other literature type
Popis súboru: text/html
Jazyk: English
ISSN: 2253-2447
DOI: 10.2147/rru.s310226
Prístupová URL adresa: https://www.dovepress.com/getfile.php?fileID=71413
https://pubmed.ncbi.nlm.nih.gov/34268257
https://doaj.org/article/a1d4a64461e94ea7bd9eabdd3c46f173
https://www.dovepress.com/the-role-of-ga-68-psma-petct-in-the-initial-staging-of-prostate-cancer-peer-reviewed-fulltext-article-RRU
https://www.dovepress.com/getfile.php?fileID=71413
https://www.dovepress.com/the-role-of-ga-68-psma-petct-in-the-initial-staging-of-prostate-cancer-peer-reviewed-fulltext-article-RRU
https://europepmc.org/article/PMC/PMC8275176
https://pubmed.ncbi.nlm.nih.gov/34268257/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275176
Rights: CC BY NC
URL: http://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at http://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (http://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php).
Prístupové číslo: edsair.doi.dedup.....6b298a6da88a0860028d4a93126c8a5f
Databáza: OpenAIRE
Popis
Abstrakt:Recommended imaging modalities for prostate cancer staging have disappointing sensitivities, whereas [68Ga]-PSMA PET/CT (PET-PSMA) shows promising sensitivities and specificities in the initial management of prostate cancer. Recent studies have revealed that a significant change of management when PET-PSMA was used, with favorable negative predictive values.In this retrospective study, we analyzed every PET-PSMA performed in our center for initial staging of intermediate and high-risk prostate cancer. Patients were divided into two groups based on whether imaging modalities other than PET-PSMA were performed. In patients submitted to radical prostatectomy, PET-PSMA findings were compared to histological analysis of the specimen.PET-PSMA results of 57 patients were gathered, with 77.2% (n=44) having performed CT scan or bone scan (BS) prior to PET-PSMA. Prostate cancer management strategy was changed in 61.4% (n=27), when PET-PSMA was performed following CT and BS. BS and CT results were consistent with PET-PSMA in 43.2% and 44.8%, respectively. In 30 cases, a curative strategy was used based on PET-PSMA findings. PET-PSMA revealed a negative predictive value of 95.2% in 23 patients submitted to radical prostatectomy with bilateral pelvic lymphadenectomy. Prostate SUV values on preoperative PET-PSMA correlated with initial PSA, ISUP grade, PC risk staging and presence of extraprostatic lesions.PET-PSMA is a key element for prostate cancer staging and management, with high diagnostic accuracy. More prospective studies need to be implemented to determine its role as a first-line staging tool.
ISSN:22532447
DOI:10.2147/rru.s310226